What type of study is this?

This is a Cohort Study study (also classified as: Animal Study, Experimental Study).

September 29, 2025Cancer Research

Abstract A104: The CA19-9 glycan is a viable target for CAR T cell therapy in PDAC

View Full Paper

Ask AI

Bookmark

CAR T cells directed against CA19-9 show significant anti-tumor potential in pancreatic ductal adenocarcinoma.
A designed CAR construct enabled a high frequency of durable complete responses in tumor models.
In vivo testing of engineered CAR T cells revealed prolonged survival in immunocompetent settings.
The feasibility of targeting CA19-9 with CAR T cells supports further clinical development.

No takes yet. Share an insight, caveat, or question.

This research explores CAR T cell therapy targeting CA19-9 in pancreatic ductal adenocarcinoma, suggesting significant anti-tumor activity.

Mo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This research explores CAR T cell therapy targeting CA19-9 in pancreatic ductal adenocarcinoma, suggesting significant anti-tumor activity.